SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-031351
Filing Date
2022-11-10
Accepted
2022-11-10 16:11:40
Documents
14
Period of Report
2022-11-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 38794
2 ex99-1.htm EX-99.1 193196
3 ex99-1_001.jpg GRAPHIC 15790
  Complete submission text file 0001493152-22-031351.txt   444719

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE lctx-20221110.xsd EX-101.SCH 3236
5 XBRL LABEL FILE lctx-20221110_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE lctx-20221110_pre.xml EX-101.PRE 22365
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3634
Mailing Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008
Business Address 2173 SALK AVENUE SUITE 200 CARLSBAD CA 92008 5105213390
Lineage Cell Therapeutics, Inc. (Filer) CIK: 0000876343 (see all company filings)

IRS No.: 943127919 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-12830 | Film No.: 221377268
SIC: 2836 Biological Products, (No Diagnostic Substances)